Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP14 | P50281 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.50 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.50 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8746847 | 1.00 | KDM4E (0.59) | KDM4EGAACA12CA14CA2 | |
| SCHEMBL5558308 | 0.90 | KDM4E (0.51) | KDM4EGAACA12CA14CA2 | |
| Hydrochloric Acid SCHEMBL8740058 | 0.88 | MAPT (0.50) | KDM4EGAACA12CA14CA2 | |
| Hydrochloric Acid SCHEMBL8740054 | 0.88 | MAPT (0.50) | KDM4EGAACA12CA14CA2 | |
| SCHEMBL15568024 | 0.85 | KDM4E (0.53) | KDM4EGAACA12CA14CA2 | |
| SCHEMBL29643419 | 0.85 | KDM4E (0.53) | KDM4EGAACA12CA14CA2 | |
| SCHEMBL7444251 | 0.85 | KDM4E (0.53) | KDM4EGAACA12CA14CA2 | |
| SCHEMBL42287 | 0.85 | CA12 (0.54) | KDM4EGAACA12CA14CA2 | |
| SCHEMBL298855 | 0.85 | CA12 (0.54) | KDM4EGAACA12CA14CA2 | |
| SCHEMBL29478385 | 0.85 | CA12 (0.54) | KDM4EGAACA12CA14CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111410647-B | Mu opium receptor bias agonist and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2021-08-17 | — | — | CN | disclosed |
| CN-111410647-A | Mu opium receptor bias agonist and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2020-07-14 | — | — | CN | disclosed |
| EP-2206704-A1 | Pharmaceutically active diazepanes | Novartis AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| EP-1874739-B1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| US-7419976-B2 | Diazepanes derivatives useful as IFA inhibitors | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| EP-1874739-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111371-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2006-10-26 | — | — | WO | disclosed |
| US-20060148780-A1 | Diazepanes derivatives useful as ifa inhibitors | OBERHAUSER BERNDT | 2006-07-06 | — | — | US | disclosed |
| EP-1590342-A1 | DIAZEPANES DERIVATIVES USEFUL AS LFA INHIBITORS | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065382-A1 | DIAZEPANES DERIVATIVES USEFUL AS LFA INHIBITORS | NOVARTIS AG (CH) | 2004-08-05 | — | — | WO | disclosed |
| WO-2003027315-A2 | AMIDASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-5985632-A | Peptide amidase from xanthomonas | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | disclosed |
| EP-0759066-A1 | PROCESS FOR OBTAINING MICRO-ORGANISMS CONTAINING PEPTIDE AMIDASE, MICRO-ORGANISMS OBTAINED THEREWITH, PEPTIDE AMIDASES CONTAINED IN THEM AND USE THEREOF | Degussa Aktiengesellschaft (DE) | 1997-02-26 | — | — | EP | disclosed |
| WO-1995030740-A1 | PROCESS FOR OBTAINING MICRO-ORGANISMS CONTAINING PEPTIDE AMIDASE, MICRO-ORGANISMS OBTAINED THEREWITH, PEPTIDE AMIDASES CONTAINED IN THEM AND USE THEREOF | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | VCAM1, ICAM1, CD69 | KDM4E 2996/4885GAA 2633/4885CA12 3493/4885 |
| US-20060148780-A1 | Diazepanes derivatives useful as ifa inhibitors | ICAM1, VCAM1, FLI1 | KDM4E 2753/4885GAA 2315/4885CA12 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.